Remission And relapse of myasthenia gravis on long-term azathioprine: An ambispective study

被引：13

作者：

Gupta, Anirban ^{[1
]}

Goyal, Vinay ^{[1
]}

Srivastava, Achal Kumar ^{[1
]}

Shukla, Garima ^{[1
]}

Behari, Madhuri ^{[1
]}

机构：

[1] All India Inst Med Sci, Cardiothorac & Neurosci Ctr, Dept Neurol, Room 706, New Delhi 110029, India

来源：

MUSCLE & NERVE | 2016年 / 54卷 / 03期

关键词：

azathioprine; complete stable remission; myasthenia gravis; relapse; remission; side effects; THYMECTOMY; TRIAL;

D O I：

10.1002/mus.25052

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Introduction: Azathioprine (AZA) is commonly used in myasthenia gravis (MG). Treatment may be prolonged, entailing significant risks and avoidable costs. Methods: We reviewed remission, relapse, and side-effect profiles in MG patients on AZA during treatment and after tapering off. We conducted an ambispective study and analyzed remission, relapse rates, and side-effect profiles in 117MG patients on AZA. Results: Thirty-nine patients (33.3%) achieved remission, and 36 (30.8%) achieved complete stable remission (CSR), with a 33% relapse rate. No AZA side effects were seen in 95 (81%) patients. Only duration of disease of >10 years (odds ratio 9.5, 95% confidence interval 2.4-36.9, P=0.001) was significantly associated with remission. Conclusions: AZA is well tolerated by MG patients, and about 30% go into CSR on long-term AZA. Muscle Nerve, 2016 Muscle Nerve54: 405-412, 2016

引用

页码：405 / 412

页数：8

共 27 条

[1]

[Anonymous], 1993, J NEUROL NEUROSURG P

[2] Complete stable remission and autoantibody specificity in myasthenia gravis [J].